Agreement signed as part of Ontario's life sciences trade mission to Israel
TEL AVIV and TORONTO (May 16, 2016) – BioLineRx Ltd. a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a framework collaboration agreement with MaRS Innovation, the commercialization agent for 15 of Toronto's top academic institutions.
Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of start-up companies originating from MaRS Innovation's members to identify in-licensing, co-development or other ...
TORONTO (May 11, 2016) – Johnson & Johnson Innovation LLC, today announced the opening of JLABS @ Toronto, a new 40,000-square-foot life sciences incubator, providing entrepreneurs shared lab space and offices, modular lab suites and access to scientific, industry and capital funding experts as they work to build important and successful early-stage companies. The new JLABS facility can accommodate up to 50 start-ups and opens with 22 companies that represent a range of sectors including therapeutics, medical devices and consumer health ...
Montreal-based venture capital fund and entrepreneurship program brings over $20 million in funding and deep expertise in consumer electronics to MI members; first deal in speech recognition
TORONTO and MONTREAL, (May 3, 2016) — MaRS Innovation, the commercialization agent for fifteen of Toronto’s top academic institutions, and TandemLaunch, a Montreal-based venture capital fund and startup incubator that specializes in consumer electronics have formed a strategic partnership (see the Areas of Interest chart below for examples). The partnership will co-develop promising technology emerging ...
It’s been a busy quarter for UTEST company TrendMD. Fresh off their participation in Ycombinator’s Winter 2016 cohort, which was covered in TechCrunch, the company has announced partnerships with HighWire and Integra.
TrendMD, a Canadian start-up company, is a content recommendation engine for scholarly publishers. They work with over 2,000 medical journals by organizing and tailoring information to the appropriate audiences. This functionality creates several opportunities for various researchers to promote their research and clinical practices in their respective fields.
TrendMD launched through ...
Company initiating two new clinical trials for recurrent and newly diagnosed malignant gliomas
TORONTO and SAN DIEGO, (May 03, 2016) – Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that it is expanding its current collaboration with Celgene Corp. in the development of marizomib for the potential treatment of malignant gliomas.
The two companies will collaborate on a Phase 2 study using marizomib (MRZ) as monotherapy in recurrent glioblastoma, as well as a Phase ...
Partnership expected to revolutionize the supply of transplantable lungs, with market launch in Europe by XENiOS® expected in 2017
HEILBRONN, Germany and TORONTO, Canada — XENiOS®, a commercial-stage medical device company, announced today it has invested $2.6 million in XOR-Labs Toronto (“XOR”), a spin-off of Toronto General Hospital at University Health Network (UHN), the world’s leading center for lung transplantation, created in partnership with MaRS Innovation.
This announcement was covered in FierceMedicalDevices and Cystic Fibrosis News Today.
VICE featured XOR's life-saving lung transplant technology ...
MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring
VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence for the Commercialization of Research (CECR), and its partner BDC Capital today announced their second joint investment in ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis).
Accel-Rx and BDC Capital, and other investors including MaRS Innovation, have invested a total of $2 million in ScarX. This investment will ...
TORONTO and SAN DIEGO (December 8, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that positive results from its ongoing Phase 1 proof-of-concept study evaluating marizomib in patients with relapsed and refractory multiple myeloma will be presented at the 57th Annual Meeting of the American Society of Hematology (ASH).
The company will also present preclinical data on marizomib demonstrating synergistic activity in combination with pomalidomide. Marizomib is a novel ...
TORONTO, ON (September 30, 2015) — Encycle Therapeutics, Inc., a University of Toronto spin-off company created in partnership with MaRS Innovation, announced today that it has completed a $2.85 million (CAD) financing led by Takeda Pharmaceutical Company Ltd. through its venture capital arm, Takeda Ventures, Inc., with Accel-Rx Health Sciences Accelerator, BDC Capital and MaRS Investment Accelerator Fund.
This news was covered in PEHub, BetaKit and TechVibes.
The funding will support ongoing development of Encycle’s unique nacellin platform chemistry and advance the company’s ...
Prima IP co-sponsoring the Ryerson University and St. Michael’s Hospital event
When your business demands staying current with the newest inventions springing up across 15 academic members, keeping pace with what’s happening is half the challenge.
That’s part of the reason why MaRS Innovation and Prima IP are sponsoring winners of an Angels’ Den competition involving the Institute for Biomedical Engineering, Science and Technology (iBEST).
iBEST is a partnership between Ryerson University and St. Michael's Hospital that brings together Ryerson's engineering and science strengths ...